Skip to main content
. 2022 May 3;12:894836. doi: 10.3389/fcimb.2022.894836

Figure 3.

Figure 3

Mutational signatures in HBV-positive and HBV-negative samples. (A) Genetic profiles of seven HBV-positive and nine HBV-negative gastric cancer (GC) samples. (B) Comparison of the most frequently mutated genes between the HBV-positive and HBV-negative GC samples. (C) Expression analysis of KMT2B, FGF12, and TUBB2B in 32 pairs of GC and non‐tumor tissues from The Cancer Genome Atlas (TCGA) database. (D) Overall survival based on the expression levels of KMT2B, FGF12, and TUBB2B in 346 patients with GC from TCGA database by Kaplan-Meier curves analysis; (E) Gene Ontology annotation analysis of frequently mutated genes in GC (mutation frequency ≥ 2, P < 0.05). HBV, hepatitis B virus; HBV-positive, positive for HBsAg or anti-HBs, anti-HBe, and anti-HBc; HBV-negative, negative for HBsAg, HBeAg, anti-HBe, anti-HBs, and anti-HBc. ***P < 0.001.